PeptiCRAd – A Novel Oncolytic Virus Based Peptide Vaccine Delivery Platform

Time: 4:30 pm
day: Day Two


  • Combining PeptiCRAd technology with oncolytic adenovirus and peptide vaccine proving a flexible therapeutic vaccine platform focused on generating cytotoxic T-cell responses against multiple tumor antigens simultaneously
  • Local intratumoral treatment with PeptiCRAd creates systemic anti-tumor T-cell immunity and is synergistic with checkpoint blockade therapy
  • First-in-human clinical trial in combination with PeptiCRAd-1 and pembrolizumab starting H2/2022